Position Statement about Gender-Neutral HPV Vaccination in Korea

Abstract

Given the rising incidence of human papillomavirus (HPV)-related diseases, including cervical, penile, and oropharyngeal cancers, particularly among men, the implementation of comprehensive HPV vaccination strategies is necessary in South Korea. This position statement advocates the introduction of gender-neutral vaccination (GNV) in the country. It recommends the administration of the HPV vaccine to both men and women aged 9-26 years to prevent a broad spectrum of HPV-related conditions. Specifically, individuals aged 9-14 years are advised to receive two doses of the vaccine, whereas those aged 15-26 years are advised to receive three doses. The optimal age for vaccination is identified as 11-12 years old. Additionally, this statement recommends that women aged 27 years and older be vaccinated based on the discretion of healthcare providers. The introduction of GNV is essential to curb the spread of HPV and reduce the overall burden of HPV-related cancers, making it a critical public health initiative in Korea.